Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Employees - 26700,
CEO - Mr. Robert A. Bradway,
Sector - Healthcare,
Country - US,
Market Cap - 142.76B
Altman ZScore(max is 10): 1.33, Piotroski Score(max is 10): 6, Working Capital: $6454000000, Total Assets: $90883000000, Retained Earnings: $-25530000000, EBIT: 7475000000, Total Liabilities: $83356000000, Revenue: $32428000000
AryaFin Target Price - $520.76 - Current Price $263.38 - Analyst Target Price $322.83
Ticker | AMGN |
Index | DJIA, NDX, S&P 500 |
Curent Price | 263.38 |
Change | 0.84% |
Market Cap | 142.76B |
Average Volume | 3.22M |
Income | 4.23B |
Sales | 32.32B |
Book Value/Share | 14.00 |
Cash/Share | 16.62 |
Dividend Est | 9.07 (3.44%) |
Dividend TTM | 9.00 (3.42%) |
Dividend Ex-Date | Feb 14, 2025 |
Employees | 26700 |
Moving Avg 20days | -4.23% |
Moving Avg 50days | -11.37% |
Moving Avg 200days | -13.65% |
Shares Outstanding | 537.50M |
Earnings Date | Oct 30 AMC |
Inst. Ownership | 78.06% |
Price/Earnings | 33.72 |
Forwad P/E | 12.69 |
PE Growth | 6.74 |
Price/Sales | 4.42 |
Price/Book | 18.81 |
Price/Cash | 15.84 |
Price/FCF | 22.72 |
Quick Ratio | 0.96 |
Current Ratio | 1.32 |
Debt/Equity | 8.02 |
Return on Assets | 4.66% |
Return on Equity | 55.72% |
Return on Investment | 6.57% |
Gross Margin | 60.22% |
Ops Margin | 20.14% |
Profit Margin | 13.09% |
RSI | 31.29 |
BETA(β) | 0.55 |
From 52week Low | 3.98% |
From 52week High | -24.07% |
EPS | 7.81 |
EPS next Year | 20.75 |
EPS next Qtr | 5.04 |
EPS this Year | 4.98% |
EPS next 5 Year | 5.00% |
EPS past 5 Year | -0.22% |
Sales past 5 Year | 3.42% |
EPS Y/Y | -44.30% |
Sales Y/Y | 21.38% |
EPS Q/Q | 62.38% |
Sales Q/Q | 23.11% |
Sales Surprise | 0.06% |
EPS Surprise | 5.79% |
ATR(14) | 7.22 |
Perf Week | -2.68% |
Perf Month | -8.51% |
Perf Quarter | -21.52% |
Perf Year | -4.29% |
Perf YTD | -8.55% |
Target Price | 322.83 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer